Afshin Dowlati, MD
Professor of Medicine
Rosalie and Morton A. Cohen Chair in Lung Cancer
Lucile and Robert Gries Endowed Director, Center for Lung Cancer Drug Development
Case Western Reserve University & University Hospitals
Afshin Dowlati, MD, is a professor of medicine at Case Western Reserve University in Cleveland Ohio. He is also the Rosalie and Morton A. Cohen Chair in Lung Cancer and the Lucile and Robert Gries Endowed Director of the Center for Lung Cancer Drug Development.
Dr. Dowlati earned his medical degree from the University of Liège school of medicine in Liège, Belgium, where he also completed his residency in internal medicine. He underwent further training as a resident in internal medicine and as a fellow in hematology/medical oncology at Case Western Reserve.
He specializes in the biology and clinical management of thoracic malignancies and has more than a decade of experience with these cancers. He has led the thoracic program At Case since 2000, seeing about 700 new referrals for lung cancer annually; about 60 of these cases are small cell lung cancers. His expertise lies in the translational aspect of target validation and drug development. Dr. Dowlati conducts preclinical studies of novel drugs with the goal of taking them to the clinic. The focus of his research laboratory is the identification of novel agents for small-cell lung cancer that can be validated in preclinical studies and translated into clinical trials. Currently, he is the director of phase 1 clinical trials at the University hospitals.
Dr. Dowlati is a member of the American Society of Clinical Oncology, American Association for Cancer Research, and the Eastern Cooperative Oncology Group.
Author or co-author of more than 146 articles in peer-reviewed journals including Clinical Cancer Research, Clinical Pharmacology and Therapeutics, The Oncologist, Translational Lung Cancer Research, Journal of Thoracic Oncology, and Annals of Oncology, to name but a few, he is a frequent presenter at medical congresses.